Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 5 | 12 |
| List of Tables | 8 | 5 |
| List of Figures | 13 | 4 |
| Introduction | 17 | 1 |
| GlobalData Report Guidance | 17 | 1 |
| Overview of Pharmaceutical and Medical Device Markets | 18 | 103 |
| Pharmaceutical Market | 18 | 1 |
| Market Overview | 18 | 3 |
| Pharmaceutical Exports and Imports | 21 | 1 |
| Supply Channels | 22 | 1 |
| Wholesalers/Distributors | 23 | 1 |
| Pharmacists and Hospitals | 23 | 1 |
| Manufacturers | 24 | 1 |
| Market Segments | 24 | 1 |
| Generic Drugs | 24 | 1 |
| Biologics/Biosimilars | 25 | 1 |
| Over-the-Counter Drugs | 26 | 1 |
| Overview of Top Five Disease Areas | 27 | 1 |
| Central Nervous System | 28 | 1 |
| Cardiovascular System | 28 | 1 |
| Anti-neoplastic and Immunomodulating Agents | 29 | 1 |
| Alimentary Tract and Metabolism | 29 | 1 |
| Respiratory System | 29 | 1 |
| Major Players | 29 | 1 |
| Alphapharm | 30 | 1 |
| Overview | 30 | 1 |
| Product Portfolio | 31 | 1 |
| Research and Development | 31 | 1 |
| SWOT Analysis | 32 | 1 |
| Apotex | 33 | 1 |
| Overview | 33 | 1 |
| Product Portfolio | 34 | 1 |
| Research and Development | 35 | 1 |
| SWOT Analysis | 35 | 4 |
| Aspen Pharmacare | 39 | 1 |
| Overview | 39 | 1 |
| Product Portfolio | 40 | 1 |
| Research and Development | 41 | 1 |
| SWOT Analysis | 41 | 4 |
| Pfizer | 45 | 1 |
| Overview | 45 | 1 |
| Product Portfolio | 46 | 1 |
| Research and Development | 47 | 1 |
| SWOT Analysis | 48 | 7 |
| AstraZeneca | 55 | 1 |
| Overview | 55 | 1 |
| Product Portfolio | 56 | 1 |
| Research and Development | 57 | 4 |
| SWOT Analysis | 61 | 8 |
| Medical Device Market | 69 | 1 |
| Market Overview | 69 | 3 |
| Overview of the Top Five Segments | 72 | 1 |
| In Vitro Diagnostics | 73 | 2 |
| Orthopedic Devices | 75 | 2 |
| Cardiovascular Devices | 77 | 2 |
| Diagnostic Imaging | 79 | 2 |
| Ophthalmic Devices | 81 | 2 |
| Major Players | 83 | 1 |
| GE Healthcare | 84 | 1 |
| Overview | 84 | 1 |
| Product Portfolio | 84 | 2 |
| Research and Development | 86 | 2 |
| SWOT Analysis | 88 | 6 |
| Siemens Healthcare | 94 | 1 |
| Overview | 94 | 1 |
| Product Portfolio | 95 | 1 |
| Research and Development | 95 | 1 |
| SWOT Analysis | 96 | 6 |
| Philips Healthcare | 102 | 1 |
| Overview | 102 | 1 |
| Product Portfolio | 102 | 1 |
| Research and Development | 103 | 1 |
| SWOT Analysis | 103 | 5 |
| GlaxoSmithKline | 108 | 1 |
| Overview | 108 | 1 |
| Product Portfolio | 109 | 1 |
| Research and Development | 110 | 1 |
| SWOT Analysis | 110 | 6 |
| Alcon | 116 | 1 |
| Overview | 116 | 1 |
| Product Portfolio | 117 | 1 |
| Research and Development | 117 | 1 |
| Market Drivers and Barriers | 118 | 1 |
| Drivers | 118 | 1 |
| Barriers | 119 | 2 |
| Market Access | 121 | 42 |
| Reimbursement and Payer Landscape | 121 | 1 |
| Overview of Healthcare System | 121 | 1 |
| Reimbursement Process | 121 | 4 |
| Reimbursement Process for Pharmaceutical Products | 125 | 2 |
| Reimbursement Process for Medical Devices | 127 | 1 |
| Overview of Insurance Providers | 128 | 1 |
| Public Insurance | 128 | 2 |
| Private Insurance | 130 | 4 |
| Patient Share in Healthcare Spending | 134 | 1 |
| Price Trend in Healthcare Services | 135 | 1 |
| Pricing Policies | 136 | 1 |
| Cost Plus Method | 136 | 1 |
| Reference Pricing | 137 | 1 |
| Weighted Average Monthly Treatment Cost | 137 | 1 |
| Regulatory Landscape | 138 | 1 |
| Overview of Regulatory Agencies | 138 | 1 |
| Market Authorization Procedure for Pharmaceutical Products | 139 | 4 |
| New Medical Device Approval Process | 143 | 6 |
| Licensing Process for Pharmaceutical and Medical Device Manufacturing | 149 | 1 |
| Licensing Process for Pharmaceutical Exports and Imports | 150 | 1 |
| Intellectual Property Rights | 151 | 1 |
| Patents | 151 | 3 |
| Trademarks | 154 | 1 |
| Clinical Trial Regulations | 155 | 2 |
| Pharmaceutical Advertising Regulations | 157 | 2 |
| Pharmacy Regulations | 159 | 1 |
| Labeling and Packaging Regulations | 160 | 3 |
| Country Analysis | 163 | 67 |
| Political Environment | 163 | 1 |
| Political Structure | 163 | 2 |
| Current Political Environment | 165 | 1 |
| Healthcare Policy Initiatives | 165 | 2 |
| Economic Landscape | 167 | 3 |
| Economic Indicators | 170 | 1 |
| Gross Domestic Product | 170 | 1 |
| GDP per Capita | 170 | 2 |
| Annual Change in GDP | 172 | 2 |
| Gross National Income | 174 | 1 |
| Inflation | 175 | 1 |
| Consumer Price Index | 175 | 2 |
| Annual Change in Consumer Price | 177 | 2 |
| Currency Exchange Rate | 179 | 1 |
| Foreign Direct Investment | 180 | 1 |
| Foreign Exchange Reserves | 181 | 1 |
| Trade Balance | 182 | 1 |
| Imports of Goods and Services | 182 | 1 |
| Exports of Goods and Services | 183 | 1 |
| Government Structural Balance | 184 | 1 |
| Government Net Debt | 185 | 2 |
| Major Industries | 187 | 1 |
| Demographics | 188 | 1 |
| Population | 188 | 3 |
| Urban and Rural Population Shares | 191 | 1 |
| Distribution by Age Groups | 192 | 3 |
| Birth Rate | 195 | 1 |
| Mortality | 196 | 1 |
| Major Causes of Mortality | 197 | 1 |
| Health Status by Gender and Age | 198 | 4 |
| Gender Ratio | 202 | 1 |
| Life Expectancy | 203 | 1 |
| Education and Literacy | 204 | 4 |
| Employment | 208 | 1 |
| Disease Burden | 209 | 1 |
| Healthcare Infrastructure | 210 | 1 |
| Healthcare Facilities | 210 | 1 |
| Public and Private Hospitals | 210 | 3 |
| Diagnostic Facilities | 213 | 2 |
| Healthcare Parameters | 215 | 1 |
| Hospital-Bed-to-Population Ratio | 215 | 2 |
| Doctor-to-Population Ratio | 217 | 1 |
| Environmental Health | 218 | 1 |
| PM2.5 Emissions | 218 | 1 |
| Carbon Dioxide Emissions | 219 | 2 |
| Healthcare Personnel | 221 | 1 |
| Nurses-to-Population Ratio | 221 | 1 |
| Pharmacists-to-Population Ratio | 222 | 1 |
| Dentists-to-Population Ratio | 223 | 1 |
| Healthcare Expenditure | 224 | 1 |
| Overview | 224 | 1 |
| Major Components of Healthcare Spending | 225 | 1 |
| Public and Private Sector Share | 226 | 1 |
| Spending in Pharmaceutical Research and Development | 227 | 1 |
| Trade Associations | 228 | 1 |
| Australian Pharmaceutical Marketing and Research Group | 228 | 1 |
| Pharmacy Guild of Australia | 228 | 1 |
| Generic Medicines Industry Association | 228 | 1 |
| Trade Fairs | 229 | 1 |
| Opportunities and Challenges | 230 | 3 |
| Opportunities | 230 | 1 |
| Challenges | 231 | 2 |
| Appendix | 233 | 21 |
| Abbreviations | 233 | 4 |
| Bibliography | 237 | 13 |
| Research Methodology | 250 | 2 |
| Coverage | 250 | 1 |
| Secondary Research | 251 | 1 |
| Forecasts | 251 | 1 |
| Expert Panel | 251 | 1 |
| Disclaimer | 252 | 2 |